100314 Limited (10620297): administration
- Status
- In administration
- Administration began
- 2025-09-08
- Administrators
- Rishi Karia, Grace Jones
- Administrators' firm
- Parker Andrews
- Formerly
- Cambridge Glycoscience Ltd
- Incorporated
- 2017-02-15
- Location
- Norwich
- Industry
- 20140 Manufacture of other organic basic chemicals
Why it went into administration
- Cash flow / liquidity pressure
- HMRC / tax arrears
- Sustained trading losses
From the administrators' statement
3.1
In August 2024, management began to seek insolvency advice given the increasing financial pressure. Subsequently, in November 2024, Supplant secured $1.28m in bridge financing by way of convertible loan notes from the key investors EQT, Manta Ray, Barilla and a former investor. The funding was intended to provide short-term liquidity until the CalPERS-backed round could be concluded. Legal and advisory costs incurred in connection with this process left the Company with significant deferred trade creditor exposure, notably to Wilson Sonsini. 3.2
3.3
Administrators' statement of proposals (2025-09-17) · Companies House register